Soligenix is a biopharmaceutical company focused on developing vaccines and medications in two specific areas: (1) a biotherapeutics segment for the development of orphan drugs designed to treat inflammatory diseases such as pediatric Crohn’s disease, oral mucositis, and acute radiation enteritis; (2) vaccines/biodefense for treatment against bioterrorism agents. The company is currently in product development with new heat stable vaccines and has been granted a $9.4 million award from the NIAID supporting product development. The Company is headquartered in Princeton, N.J. For more information, visit the company’s Web site at www.soligenix.com